AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE

Summary

The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF). The primary objective of the study is to evaluate the efficacy of Aspirin versus Aspirin + Clopidogrel after LAAC by comparing the occurrence of ischemic lesions on cerebrovascular magnetic resonance imaging (MRI) studies.

Eligibility

Inclusion Criteria:

* Male or female patients with LAAC indication according to "Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé" (CNEDiMTS) (National Commission for the Evaluation of Medical Devices and Health Technologies) guidelines
* Age ≥ 18 years
* Written informed consent provided by the patient
* Heart team approval: multidisciplinary team including interventional cardiologists, neurologists and other physicians discussing the definitive contraindication for anticoagulation
* Registration under social security system

Exclusion Criteria:

* Minors
* Unacceptable bleeding risk with double antiplatelet therapy decided by the physician who contraindicated oral anticoagulation
* LAAC contraindication : left appendage thrombus
* Major disease resulting in a life expectancy of \< 1 year
* Severe and inherited bleeding disorder
* Known hypersensitivity to aspirin and/or clopidogrel:

  * Hypersensitivity to clopidogrel, acetylsalicylic acid, or one of the excipients or other nonsteroidal anti-inflammatory drugs (cross-reaction).
  * Asthma or a history of asthma with or without nasal polyps induced by salicylates or substances of close activity, including nonsteroidal anti-inflammatory drugs.
  * Evolving peptic ulcer or history of gastric hemorrhage or perforation after treatment with acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.
  * Any constitutional or acquired haemorrhagic disease.
  * Patients with mastocytosis, in whom the use of acetylsalicylic acid can lead to severe hypersensitivity reactions (including circulatory shocks with flushing, hypotension, tachycardia and vomiting).
  * Severe liver failure.
  * Severe kidney failure (Creatinine light \< 30ml/min).
  * Uncontrolled severe heart failure
* Contraindication to MRI: claustrophobia or inability to lie still for exam time, implantable pacemaker or defibrillator, intracorporeal metal foreign body (especially intraocular), intracranial metal clip, cochlear implant, cardiac valve prosthesis type Starr-Edwards pre 6000, or biomedical device type insulin pump or neurostimulator.
* Guardianship
* Curatorship
* Pregnancy or child-bearing potential female
* Woman of childbearing age who does not benefit from highly effective contraception (CTFG recommendation on highly effective contraceptive methods: oral, intravaginal or transdermal estrogeno-progestin contraception; progestin-based oral, injectable or implantable contraception; intrauterine device; hormonal intrauterine device; female sterilization (occlusion of the fallopian tubes))
* Iode contraindication
* Patient already participating in another category 1 interventional research
* Patient in a period of exclusion relative to another research protocol.

Conditions6

Interventions2

Related trials

• ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography — Jung-min Ahn
• Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention — Peking Union Medical College Hospital
• COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes — Montreal Heart Institute
• Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI — Medical University of Gdansk
• Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization — Takeshi Morimoto
• IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome — Shanghai Zhongshan Hospital
• Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation — Insel Gruppe AG, University Hospital Bern
• Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation — Kyoto University

Browse More Trials